Annovis Bio Files 8-K: Board and Compensation Updates
Ticker: ANVS · Form: 8-K · Filed: May 1, 2024 · CIK: 1477845
| Field | Detail |
|---|---|
| Company | Annovis Bio, Inc. (ANVS) |
| Form Type | 8-K |
| Filed Date | May 1, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, filing
Related Tickers: ANVS
TL;DR
Annovis Bio (ANVS) filed an 8-K on May 1st for board changes and compensation. Watch for details.
AI Summary
Annovis Bio, Inc. filed an 8-K on May 1, 2024, reporting changes in its board of directors and executive compensation arrangements. The filing also includes financial statements and exhibits, though specific details on dollar amounts or new appointments were not immediately available in the provided text.
Why It Matters
Changes in a company's board of directors and executive compensation can signal shifts in strategy, governance, or financial outlook, impacting investor confidence.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information, and changes in leadership or compensation can introduce uncertainty or signal strategic shifts.
Key Players & Entities
- Annovis Bio, Inc. (company) — Registrant
- May 1, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 101 Lindenwood Drive, Suite 225 (address) — Principal Executive Offices
- Malvern, PA (location) — Principal Executive Offices City and State
- 19355 (zip_code) — Principal Executive Offices Zip Code
- 484-875-3192 (phone_number) — Registrant's Telephone Number
FAQ
What specific changes were made to the board of directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers', but the specific names and details of these changes are not provided in the excerpt.
What are the details of the new compensatory arrangements?
The filing mentions 'Compensatory Arrangements of Certain Officers', but the specific terms, amounts, or beneficiaries of these arrangements are not detailed in the provided text.
What financial statements or exhibits are included with this filing?
The filing states 'Financial Statements and Exhibits' are included, but the content or nature of these documents is not specified in the excerpt.
When was Annovis Bio, Inc. incorporated?
Annovis Bio, Inc. was incorporated in Delaware.
What is the primary business of Annovis Bio, Inc. according to the filing?
The Standard Industrial Classification (SIC) code indicates the company is in 'PHARMACEUTICAL PREPARATIONS [2834]'.
Filing Stats: 886 words · 4 min read · ~3 pages · Grade level 12.5 · Accepted 2024-05-01 17:18:07
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 per share ANVS New York Stock Exchang
Filing Documents
- tm2413238d1_8k.htm (8-K) — 33KB
- tm2413238d1_ex10-1.htm (EX-10.1) — 69KB
- 0001104659-24-055838.txt ( ) — 289KB
- anvs-20240501.xsd (EX-101.SCH) — 3KB
- anvs-20240501_lab.xml (EX-101.LAB) — 33KB
- anvs-20240501_pre.xml (EX-101.PRE) — 22KB
- tm2413238d1_8k_htm.xml (XML) — 4KB
02 Departure
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Effective as of the close of business on April 30, 2024, Henry Hagopian is no longer serving as the Chief Financial Officer and as principal financial officer of Annovis Bio, Inc. (the "Company"). Mr. Hagopian is stepping down from these positions to pursue other opportunities. Mr. Hagopian's resignation was not due to any disagreement or dispute with the Company or the Board of Directors of the Company (the "Board") regarding any matter, including the Company's accounting principles, practices, financial statement disclosures or compliance procedures. The Board thanks Mr. Hagopian for his service to the Company and wishes him well in his future endeavors. On May 1, 2024, the Board appointed Maria Maccecchini, the Company's President and Chief Executive Officer, as the interim principal financial officer, effective immediately, in light of Mr. Hagopian's departure. In connection with Mr. Hagopian's departure from the Company, the Company and Mr. Hagopian have entered into a Separation Agreement and General Release (the "Separation Agreement"), dated as of April 30, 2024 (the "Separation Date"), pursuant to which the Company and Mr. Hagopian have agreed upon the terms of Mr. Hagopian's separation from the Company. Pursuant to the Separation Agreement, Mr. Hagopian has agreed to comply with certain confidentiality and cooperation provisions. The Separation Agreement also provides for a customary general release of claims and the following severance benefits: two (2) months of Mr. Hagopian's base salary, less applicable taxes and withholding, payable in a single lump sum on the Company's first regularly scheduled payroll pay date after the Separation Date; two (2) months of reimbursement of medical and dental insurance premiums following the Separation Date, payable in a single lump sum on the Company's first
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: May 1, 2024 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer